Drugs / AMCASERTIB
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02483247 | Sep 2015 → May 2019 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02432326 | Apr 2015 → Dec 2019 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02354898 | Mar 2015 → Oct 2018 | hepatocellular carcinoma | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01781455 | Feb 2012 → Jun 2020 | cancer of unknown primary site | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02279719 | Dec 2014 → Jul 2019 | hepatocellular carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02232620 | Mar → Jul 2017 | gastrointestinal stromal tumor | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02232646 | Jan 2017 → Aug 2018 | renal cell carcinoma, urothelial carcinoma | Sumitomo Pharma America, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02432690 | Jun 2015 → Jan 2017 | ovarian cancer | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02232633 | Feb 2015 → Dec 2017 | cholangiocarcinoma, hepatocellular carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMCASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707349 ↗ |
| Known as | BBI503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02432690 ↗ |
| Modality | Small molecule | — CHEMBL3707349 ↗ |
| Route | Oral | “BBI503 will be administered orally” NCT02232620 ↗ |